WESTMINSTER, Colo., November 18, 2025--(BUSINESS WIRE)--TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for ...
Earnings call TriSalus Life Sciences reported Q3 2025 revenue of $11.6M, up 57% YoY and 3% QoQ, driven by expanding adoption of its TriNav platform. Management reaffirmed 50% FY revenue growth ...
Hosted on MSN
TriSalus reaffirms 50% revenue growth target while advancing TriNav platform and product launches
CEO Mary Szela reported strong third quarter results, highlighting revenue of $11.6 million, a 57% increase year-over-year and 3% sequential growth. She noted continued expansion of the TriNav ...
We believe TriNav is well positioned to become the standard of care in liver embolization for complex patients. To accelerate this trajectory, we are executing a focused strategy centered on 3 pillars ...
Expanded Patient Access: The TriNav LV Infusion System is tailored for larger vessels (3.5-5.0 mm), increasing the number of patients eligible for TriSalus' proprietary Pressure-Enabled Drug Delivery ...
DENVER & SALT LAKE CITY--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided ...
(RTTNews) - TriSalus Life Sciences, Inc. (TLSI) has unveiled the TriNav FLX Infusion System, a new addition to its TriNav portfolio. The latest system enhances trackability and flexibility, allowing ...
– Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker, ...
DENVER, November 07, 2024--(BUSINESS WIRE)--TriSalus Life Sciences ® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results